Human Genome Sciences Stock Price and Value Analysis

Human Genome Sciences (NASDAQ:HGSI) in our automated value investing analysis, with the cash flow history and price comparison below.

Key Facts

  • Ticker: HGSI (NASDAQ)
  • Current price: $0.00
  • Sector: Unknown
  • Industry: Unknown

Advertisement helps keep Trendshare free for most readers.

Hold-time calculator

Estimate how long you need to hold Human Genome Sciences to reach your target.

Target type
AdvantagesDisadvantagesNeutral
None.
  • This company has wild ups and downs.
  • This company is less known than others.
  • This company is not making money.
  • This stock looks overpriced.
  • This company pays no dividend.

Inside the HGSI Numbers

HGSI Price
(Human Genome Sciences stock price per share)
$0.00
[?] PE Ratio versus Sector 100% lower than other Unknown stocks
[?] PE Ratio versus Industry 100% lower than other Unknown stocks
[?] Cash Yield -14.64%
[?] Free Cash Flow Jitter 43%

Insider Activity Summary

No open-market insider buys or sells are recorded for the last 12 months.

Related guides: good annual rate of return · high-yield stocks · forecasting earnings growth

Free Cash Flow by Fiscal Year

Each year names the SEC filer that reported it, so a change of filer shows up here.

Fiscal yearSEC filer (CIK)Free cash flow (USD millions)
2009 901219 -10.4
2010 901219 -290.6
2011 901219 -410.8

Download the yearly data as CSV.

Price Versus Our Estimated Value

None of the 3 fiscal years we have for Human Genome Sciences under its current SEC filer shows positive free cash flow.

Year-to-year variability in free cash flow is volatile, measured at 43%.

We do not estimate a fair value for Human Genome Sciences while its free cash flow growth is not positive, so there is no value comparison here.

No dividend yield is recorded for Human Genome Sciences in our data.

These figures are automated calculations from SEC filings and the recent price. They are not a recommendation to buy or sell. See how we estimate value.

SEC Filer History

Every fiscal year on this page is reported by one SEC filer, CIK 901219.

Each figure on this page comes from that filer.

Risks to This Analysis

  • Only 3 years of cash-flow data from the current SEC filer are available. Averages and trends rest on a short record.
  • Free cash flow was negative in 3 of the 3 years we have.
  • Free cash flow is volatile from year to year, so the estimates depend heavily on which years are included.
  • We have no value estimate for this stock, so no price comparison is made.
  • This page's data was last updated on 2026-09-18. Prices and filings may have changed since.
  • These figures are automated calculations from SEC filings and the recent price. They may contain errors, and they do not reflect lawsuits, management changes, or other events the filings do not show.

Advertisement supports free stock analysis content.

Questions to Answer Before You Invest in HGSI

Does Human Genome Sciences have a coherent story? Does it have a plan to continue to make money? Is it worth your time? Only you can decide where to go from here. Our investment guide helps you ask the right questions, including how to buy stocks. Use these research links for more information.

Worked example: HGSI

This example shows how we apply the Trendshare checklist to HGSI: earnings power, cash generation, valuation, and margin of safety.

We check: business quality, free cash flow, P/E, and margin of safety.

  1. Step 1 — Snapshot

    • Price: 0.00
    • Market cap: —
    • EPS: —
  2. Step 2 — Valuation checks

    • P/E: —
    • FCF yield: —
    • Date checked: Sep 18, 2026
  3. Step 3 — Margin of safety

    • Compare price to fair value and safety price.
    • Look for durable cash generation and reasonable leverage.
    • Decide if it passes your personal checklist.